EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Checkpoint Inhibitor–Associated Autoimmune Diabetes Following PD-1 Blockade: Severe Diabetic Ketoacidosis After Pembrolizumab

Divya Samat, Osadebamwen Osaghae, Shivam Singh, Mohammad Abu Tineh, Anthony Donato

Advances in Clinical Medical Research and Healthcare Delivery · 17.05.2026 · 6 (2) · 40-44

DOI: 10.53785/2769-2779.1377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical Medical Research and Healthcare Delivery, online erschienen am 17.05.2026. Verfasst von Divya Samat und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by enhancing antitumor T-cell activity through blockade of inhibitory pathways including programmed cell death protein 1 (PD-1) and its ligand (PD-L1). Loss of immune tolerance can lead to immune-related adverse events (irAEs), including endocrine toxicities. Checkpoint inhibitor–associated autoimmune diabetes (CIADM) is rare but clinically significant because it often presents abruptly with diabetic ketoacidosis (DKA) and profound insulin deficiency. We describe an 81-year-old male with stage III clear-cell renal cell carcinoma who developed abrupt-onset autoimmune diabetes 8 weeks after initiating adjuvant pembrolizumab. The patient presented with severe hyperglycemia and high anion-gap metabolic acidosis consistent with DKA. HbA1c had increased from 5.7% three months earlier to 9.0% at presentation, supporting recent onset sustained hyperglycemia. C-peptide levels were 0.61 ng/mL (laboratory reference 0.80–3.85 ng/mL), and autoimmune markers were negative (glutamic acid decarboxylase antibody

Zitieren

APA

Samat, D., Osaghae, O., Singh, S., Tineh, M. A., & Donato, A. (2026). Checkpoint Inhibitor–Associated Autoimmune Diabetes Following PD-1 Blockade: Severe Diabetic Ketoacidosis After Pembrolizumab. Advances in Clinical Medical Research and Healthcare Delivery, 6(2), 40-44. https://doi.org/10.53785/2769-2779.1377

Vancouver

Samat D, Osaghae O, Singh S, Tineh MA, Donato A. Checkpoint Inhibitor–Associated Autoimmune Diabetes Following PD-1 Blockade: Severe Diabetic Ketoacidosis After Pembrolizumab. Advances in Clinical Medical Research and Healthcare Delivery. 2026;6(2):40-44. doi:10.53785/2769-2779.1377

BibTeX
@article{Samat2026,
  author = {Samat, Divya and Osaghae, Osadebamwen and Singh, Shivam and Tineh, Mohammad Abu and Donato, Anthony},
  title = {Checkpoint Inhibitor–Associated Autoimmune Diabetes Following PD-1 Blockade: Severe Diabetic Ketoacidosis After Pembrolizumab},
  journal = {Advances in Clinical Medical Research and Healthcare Delivery},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {40--44},
  doi = {10.53785/2769-2779.1377}
}
Kostenlos starten →